About the Study
This study is looking at which dose the study drug, GSK5784283, can best help reduce airway inflammation in adults suffering from uncontrolled asthma when taken alongside their current asthma treatment. Previous research has shown promise that GSK5784283 could help to prevent asthma exacerbations with just 2 shots per year.
If you qualify and choose to participate, there is a 75% chance you will receive the study drug and a 25% chance you will receive a placebo. A placebo is an inactive material that looks like GSK5784283 but does not contain any active study drug.
You will be on this study for about 91 weeks which will include a screening period, a treatment period, and a follow-up period. The study will require up to 15 in-clinic visits. If you qualify and choose to participate, you will be compensated up to $1,500 for your study-related time and travel. Your participation is entirely voluntary, and you can leave the study at any time.